An open label randomised control trial comparing between solo prednisolone therapy versus steroid-sparing agent along with daily doses of prednisolone in achievement of remission among FRNS and SDNS patients - NIL

开始日期2024-04-20

申办/合作机构

SCB Medical College & Hospital

100 项与 SCB Medical College & Hospital 相关的临床结果

登录后查看更多信息

0 项与 SCB Medical College & Hospital 相关的专利（医药）

登录后查看更多信息

项与 SCB Medical College & Hospital 相关的文献（医药）

2024-09-28·Indian Journal of Pharmacy and Pharmacology

Tp-Te interval variation and its association with MACE as a metric of effective fibrinolysis in patients with STEMI from East India

作者: Goswami, Saurabh ; Mohabansi, Swapnil Lokesh ; Tomar, Arpit

Coronary artery disease (CAD) poses a significant health burden in India, and ST-elevation myocardial infarction (STEMI) is one of its most severe manifestations. The electrical activity is variable during STEMI, which produces dispersion and raises the T Peak-T End (Tp-Te) interval. STEMI is a medical emergency that requires prompt intervention to restore blood flow to the affected part of the heart muscle. Timely diagnosis and treatment are crucial in reducing morbidity and mortality associated with STEMI. Despite advancements in medical care, access to timely intervention and appropriate healthcare facilities remains a challenge in many parts of India, especially in rural areas. This single-center, prospective observational study included 150 STEMI patients. Clinical, demographic, and ECG data were recorded. The Tp-Te interval alterations and their relationship to major adverse cardiovascular events (MACE) in STEMI patients both during and after successful or unsuccessful fibrinolysis were examined. Patients without MACE had a significant mean decrease in the Tp-Te interval following successful fibrinolysis (i.e., 18.47 ± 5.66 ms vs. 10 ± 7.07 ms, p:0.039) compared to patients with MACE. It was found that after fibrinolysis, patients with a Tp-Te interval > 100 ms experienced much higher rates of death (4% vs. 0%, p:0.0001), arrhythmias (7.3% vs. 0.7%, p:0.0001), and heart failure (16% vs. 1.3%, p:0.0001), both while they were in the hospital and within 30 days of the index event. Our data shows that a decrease in the Tp-Te interval following fibrinolysis lowers the risk of MACE both during hospital stay and within 30 days following the index incident.

2024-07-01·Oral Oncology

“Survival patterns and prognostic factors of gingivobuccal complex squamous cell cancer: A monocentric retrospective chart audit”

Article

作者: Singh, Monika ; Ray, Satyashree ; Sharma, Gaurav ; Bhusan Kar, Indu ; Mishra, Niranjan

OBJECTIVETo analyze the impact of clinico-pathological prognostic factors on survival in patients with GBC OSCC. To evaluate the association between various clino-pathological and treatment factors influencing the 3-year and 5-year Overall survival (OS), and Disease specific survival (DSS) in patients with lower GBC OSCC.PATIENTS & METHODSAn Institutional Ethical Committee (IEC) approved retrospective chart audit was performed. Biopsy proven squamous cell cancer of gingivobuccal complex (GBC OSCC) patients from 2010 to 2019 who were treated primarily with surgery with or without adjuvant therapy having complete clinicopathological and follow up data were included. Survival outcomes including 2-year, 3-year & 5-year OS, and DSS were calculated and analyzed. A multivariate analysis was performed to identify significant predictor for the survival outcomes. A p-value < 0.05 was considered significant.RESULTS183 patients with primary OSCC were identified out of which 83 patients comprised of OSCC of lower GBC. Age (p < 0.001), tumor grade (p = 0.009), pN status (p = 0.002), PNI (p < 0.001), lymph node metastasis (p = 0.002), treatment given (p = 0.02) and adjuvant therapy (p = 0.02) were found as a significant prognostic factor in univariate analysis.CONCLUSIONThe OS & DSS of the patients with lower GBC SCC is 78.3%. The 2-year, 3-year, and 5-year OS of the study population was reported to be 95.2%, 87.9%, and 78.8% respectively. PNI & lymph node metastasis were significant prognostic factor for OS with an adjusted hazard ratio 4.91 and 7.75 respectively.

2024-07-01·Journal of Clinical and Experimental Hepatology

The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease

Article

作者: Behera, Sanatan ; Patra, Umesh C. ; Mohapatro, Arupam ; Majji, Prabir ; Pani, Manoj ; Jena, Susanta K. ; Behera, Manas K.

BackgroundThe burden of hepatitis C virus (HCV) in India is alarming, with a major share of this virus being witnessed in patients with end-stage renal disease (ESRD). A pan-genotypic combination of sofosbuvir and velpatasvir is found to be safe, effective, and economical in resource-constraint countries such as ours. However, there are scanty data on the efficacy and safety of sofosbuvir and velpatasvir combination in patients with ESRD. Hence, we performed this study to evaluate the safety and efficacy of the combination of sofosbuvir and velpatasvir in patients of chronic hepatitis C (CHC) with ESRD.MethodsThis is an observational study comprising of 40 CHC patients with ESRD on maintenance hemodialysis. All patients were treated with a fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks in case of non-cirrhotic or compensated cirrhosis and 24 weeks in case of decompensated cirrhosis. The efficacy was assessed by sustained virological response defined by negative HCV RNA at 12 weeks (sustained virological response [SVR] 12) post treatment, and safety was assessed by recording any side-effects of all patients.ResultsOut of the 40 patients enrolled in our study, majority were non-cirrhotic (77%), and all were treatment-naive. The mean age was 49.87 ± 12.13 years, and 80% patients were male. The mean baseline HCV RNA was 2.61 ± 7.83 × 10⁶ IU/ml. All the 40 patients (100%) achieved undetectable HCV RNA at the end of treatment; however, 39 patients (97.5%) achieved SVR 12. There was no significant deterioration of estimated glomerular filtration rate (eGFR) after completion of antiviral therapy as compared to the baseline eGFR (13.27 ± 10.32 vs13.54 ± 11.38, P = 0.54). None of the patients reported any serious adverse effects during treatment.ConclusionThe fixed-dose combination of sofosbuvir and velpatasvir is effective and has showed excellent safety profile in patients of CHC with ESRD.

100 项与 SCB Medical College & Hospital 相关的药物交易

登录后查看更多信息

100 项与 SCB Medical College & Hospital 相关的转化医学

登录后查看更多信息